Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Minimal Access Coronary Revascularization: Past, Present and Future

Version 1 : Received: 22 May 2023 / Approved: 24 May 2023 / Online: 24 May 2023 (02:04:38 CEST)

A peer-reviewed article of this Preprint also exists.

Purmessur, R.; Wijesena, T.; Ali, J. Minimal-Access Coronary Revascularization: Past, Present, and Future. J. Cardiovasc. Dev. Dis. 2023, 10, 326. Purmessur, R.; Wijesena, T.; Ali, J. Minimal-Access Coronary Revascularization: Past, Present, and Future. J. Cardiovasc. Dev. Dis. 2023, 10, 326.

Abstract

Minimal access cardiac surgery appears to be the future. It is increasingly desired by cardiologists and demanded by patients who perceive superiority. Minimal access coronary artery revascularisation has been increasingly adopted throughout the world. Here we review the history of minimal access coronary revascularization and see that it is almost as old as the history of cardiac surgery. Modern minimal access coronary revascularization takes a variety of forms – namely minimal access direct coronary artery bypass grafting (MIDCAB), hybrid coronary revascularisation (HCR) and totally Endoscopic Coronary Artery Bypass Grafting (TECAB). It is noteworthy that there is significant variation in nomenclature and approaches for minimal access coronary surgery and this truly presents a challenge to comparing the different methods. However, these approaches are increasing in frequency and proponents demonstrate clear advantages for their patients. The challenge that remains, as for all areas of surgery, is demonstrating superiority of these techniques over tried and tested open techniques which is very difficult. There is a paucity of randomized controlled trials to help answer this question, and the future of minimal access coronary revascularisation to some extent is dependent on such trials. Thankfully some are underway and the results eagerly anticipated.

Keywords

minimal access; coronary artery; revascularisation; MIDCAB; TECAB; HCR

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.